


in WT and p115-Tg mice. The increase in size of the p115-Tg heart is essentially the same as that in WT mice (Figure 1A-C). TAC of p115-Tg mice increased left ventricular end-systolic pressure (LVESP) to the same extent as that in WT mice (Figure 1D), indicating that pressure overload by TAC was equally performed. TAC induced a significant elevation of left ventricular end-diastolic pressure (LVEDP) in WT mice. However, there was no alteration in p115-Tg mice (Figure 1E). Although the LV systolic function in p115-Tg mice was slightly reduced in sham operation compared with that in WT mice, there was no further impairment by TAC (Figure 1E and Supplementary Table 1). These results suggest that systolic and diastolic function of the p115-Tg heart is not impaired after TAC. TAC in WT mice strongly increased the expression of messenger ribonucleic acid (mRNA) of classical markers of pathological hypertrophy in myocardium, atrial natriuretic peptide (ANP),  $\beta$ -myosin heavy chain ( $\beta$ -MHC), and  $\alpha$ -skeletal muscle actin ( $\alpha$ -SKA) (Figure 1F). However, the expression of these genes in p115-Tg hearts was less than half of that in WT hearts. We have reported that G $\alpha_{12/13}$  mediate activation of Rho and c-Jun NH<sub>2</sub>-terminal kinase (JNK) in cultured cardiomyocytes (Maruyama et al, 2002; Arai et al, 2003; Nishida et al, 2005). Pressure overload increased the activities of Rho and JNK in WT hearts, but the activation of Rho and JNK was significantly suppressed in TAC of p115-Tg hearts (Figure 1G and H). However, TAC-induced Akt activation was not suppressed in p115-Tg hearts, suggesting that p115-RGS specifically inhibits G $\alpha_{12/13}$ -

mediated signalling in the heart. As the TAC-induced Rac activation was also suppressed in p115-Tg hearts (Supplementary Figure 1E), G $\alpha_{12/13}$  may mediate TAC-induced JNK activation through Rho- and Rac-dependent pathways in mouse hearts as well as rat cardiac myocytes.

As overproduction of ECM protein causes ventricular stiffness leading to the impairment of diastolic function (Berk et al, 2007), we examined the involvement of G $\alpha_{12/13}$  in pressure overload-induced cardiac fibrosis. TAC increased the expression of collagen types I and III proteins in the interstitial tissue in WT mice, as determined by picrosirius red staining (Figure 2A). In contrast, TAC-induced collagen deposition in p115-Tg mice was less than half of that in WT mice (Figure 2B). The relationship between heart weight to body weight ratio (HW/BW) and collagen expression in WT hearts reveals that the degree of hypertrophy correlates positively with severity of fibrosis (Figure 2C). In contrast, the correlation between HW/BW and collagen expression in p115-Tg hearts also indicates that TAC-induced cardiac fibrosis was significantly suppressed despite the development of cardiac hypertrophy. TAC increased the expression of mRNAs for procollagen type I and type III, fibrogenic factors (CTGF (Hahn et al, 2000), periostin (Katsuragi et al, 2004), and TGF- $\beta$ s (Zhang et al, 2000)) in WT hearts (Figure 2D). These increases were significantly attenuated in p115-Tg hearts. Furthermore, TAC increased the expression of periostin, mature TGF- $\beta$ s, and angiotensin-converting enzyme (ACE) in WT hearts, but these increases were attenuated also in p115-Tg hearts (Figure 2E). It has been



**Figure 2** G $\alpha_{12/13}$  mediate pressure overload-induced cardiac fibrosis. (A) LV sections stained by picrosirius red. (B, C) Collagen volume fraction (CVF) (B) and correlations between HW/BW and CVF (C). (D) Expression of collagen type I, type III, CTGF, periostin, and TGF- $\beta$ 1-3 mRNAs. (E) Expression of periostin, mature TGF- $\beta$ s, and ACE proteins. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein levels were used as an internal control. Error bars indicate s.e.m.;  $n = 15-19$  (B),  $n = 3$  (D, E). Representative picrosirius red staining sections of hearts from WT ( $n = 15-19$ ) and p115-Tg ( $n = 15-16$ ) mice were shown (A). \* indicates  $P < 0.05$  and \*\* indicates  $P < 0.01$ .

postulated that activation of the renin-angiotensin-aldosterone system (RAAS) and increased levels of active TGF- $\beta$ 1 has an important function in pressure overload-induced cardiac fibrosis (Berk *et al.*, 2007). Pressure overload increased three TGF- $\beta$  mRNA isoforms and proteins in WT hearts, and these increases were suppressed in p115-Tg hearts. These results suggest that G $\alpha_{12/13}$  mediate pressure overload-induced cardiac fibrosis by an increase in induction of CTGF, periostin, and TGF- $\beta$ s.

#### Activation of G $\alpha_{13}$ in cardiomyocytes induces cardiac fibrosis

We also generated mice with cardiomyocyte-specific overexpression of a constitutively active (CA) mutant of G $\alpha_{13}$  protein (CA-G $\alpha_{13}$ ) (Supplementary Figure 2). The CA-G $\alpha_{13}$  heterozygous mice did not show an increase in heart size, compared with WT mice (Supplementary Figure 3A and B). However, collagen deposition was significantly increased (Supplementary Figure 3C). The expression of mRNA for CTGF was strongly increased in CA-G $\alpha_{13}$  mice (Supplementary Figure 3D). The expression of mRNA for ACE and protein expression were slightly increased (Supplementary Figure 3E). The expression of mRNAs for periostin and TGF- $\beta$ s was not increased, but proteins of periostin and TGF- $\beta$ s were increased in CA-G $\alpha_{13}$  hearts. As CA-G $\alpha_{13}$  increased proteins but not mRNAs for periostin and TGF- $\beta$ s, G $\alpha_{13}$  may participate in the stabilizing of periostin and TGF- $\beta$ s proteins. These results also suggest that pressure overload-induced expression of fibrogenic factors is mediated by G $\alpha_{13}$ . In contrast to CTGF, the expression of hypertrophy-related genes (ANP and  $\beta$ -MHC) was not increased in CA-G $\alpha_{13}$  heart, consistent with the inability of CA-G $\alpha_{13}$  to induce hypertrophy. However, strong activation of G $\alpha_{13}$  signalling may induce cardiac hypertrophy as well as fibrosis, as CA-G $\alpha_{13}$  homozygous mice showed a significant increase in heart size (data not shown). The LV function of CA-G $\alpha_{13}$  mice was significantly decreased compared with that of WT mice (Supplementary Figure 3F and G). These results suggest that G $\alpha_{12/13}$  mediate cardiac fibrosis and dysfunction induced by pressure overload.


#### Extracellular nucleotides mediate mechanical stretch-induced G $\alpha_{12/13}$ activation through purinergic receptors

As heterotrimeric G proteins are activated primarily by receptor stimulation, it is reasonable to assume that pressure overload activates G $\alpha_{12/13}$ -coupled receptors. As mechanical stretch of cardiomyocytes is frequently used as an *in vitro* model of pressure overload, we examined which G protein-coupled receptor(s) are involved in mechanical stress-induced G $\alpha_{12/13}$  activation. As activation of small GTP-binding protein Rho is a sensitive marker of G $\alpha_{12/13}$  activity (Kozasa *et al.*, 1998), we measured Rho activity as an index of the magnitude of G $\alpha_{12/13}$  signalling. Mechanical stretch of cardiomyocytes increased Rho activity, and this increase was sustained for 30 min (Figure 3A). Overexpression of p115-RGS completely inhibited mechanical stretch-induced Rho activation at early time and 30 min (Figure 3B and C). As a mutation in the RGS domain of p115RhoGEF loses the interaction with G $\alpha_{12/13}$  (Bhattacharyya and Wedegaertner, 2003), we expressed the mutated p115-RGS to examine whether the effects of p115-RGS are specific for inhibition of interaction with G $\alpha_{12/13}$ . Expression of the interaction-deficient mutant

of p115-RGS did not affect mechanical stretch-induced Rho activation. In addition, treatment with *Pertussis* toxin, an uncoupler of receptor-G $\alpha$  interaction, did not suppress mechanical stretch-induced Rho activation. These results suggest that mechanical stretch activates Rho through G $\alpha_{12/13}$ . It has been reported that Ang type 1 receptor (AT1R) is activated by mechanical stretch without the involvement of Ang II, and AT1R antagonist blocks mechanical stretch-induced G $\alpha_q$  activation and hypertrophic responses (Zou *et al.*, 2004). However, mechanical stretch-induced Rho activation through G $\alpha_{12/13}$  was not attenuated by treatment with not only CV11974 (AT1R antagonist) but also PD123319 (AT2R antagonist), propranolol ( $\beta$  adrenergic receptor (AR) antagonist), prazosin ( $\alpha_1$ AR antagonist), BQ123 (ET type A receptor antagonist), BQ788 (ET type B receptor antagonist) and CGP20712A (selective  $\beta_1$ AR antagonist) (Figure 3C and Supplementary Figure 4A and B). Mechanical stretch increases intracellular Ca<sup>2+</sup> concentration through mechanosensitive cation channels (Christensen and Corey, 2007). However, treatment with an inhibitor of stretch-sensitive channels GsMTx4, intracellular Ca<sup>2+</sup> chelator BAPTA-AM, and L-type Ca<sup>2+</sup> channel blocker nitrendipine did not suppress mechanical stretch-induced Rho activation (Figure 3C and D). The Src family kinase substrate p130Cas has been reported to function as a mechanosensor (Sawada *et al.*, 2006), but an Src inhibitor, PP2, did not affect mechanical stretch-induced Rho activation (data not shown). In contrast, treatment with apyrase, an ATP/ADP scavenging enzyme, completely blocked mechanical stretch-induced Rho activation (Figure 3D and Supplementary Figure 4C). Treatment with another ATP scavenging enzyme, hexokinase II, or purinergic receptor antagonists, suramin and PPADS, also suppressed mechanical stretch-induced Rho activation. Furthermore, extracellular treatment with ATP, ADP, UTP, and UDP, but not adenosine, increased Rho activity (Supplementary Figure 4D-F). The extracellular nucleotide-stimulated Rho activation was completely suppressed by the expression of p115-RGS (Supplementary Figure 4G). Mechanical stretch actually activated G $\alpha_{12}$  and G $\alpha_{13}$ , which were completely suppressed by treatment with suramin (Figure 3E and F). These results suggest that extracellular nucleotides mediate mechanical stretch-induced G $\alpha_{12/13}$  activation through purinergic receptors in rat cardiomyocytes.

#### Pannexin-1 mediates mechanical stretch-induced release of nucleotides

Extracellular ATP in the cardiovascular system may originate from different cellular sources, such as perivascular sympathetic nerve endings (Burnstock, 1972), activated platelets, endothelial cells, and inflammatory cells. It has also been postulated that connexin and pannexin hemichannels are involved in ATP release caused by mechanical stimulation in cardiac myocytes (Suadicani *et al.*, 2000; Shestopalov and Panchin, 2008). Mechanical stretch of cardiomyocytes increased extracellular ATP concentration (Figure 4A). Treatment with hemichannel inhibitors, carbenoxolone, and 1-heptanol, suppressed both mechanical stretch-induced Rho activation and the increase in extracellular ATP concentration (Figures 3D and 4B). As the increase in extracellular ATP was not affected by p115-RGS and P2 receptor antagonists (PPADS and suramin), G $\alpha_{12/13}$  do not participate in ATP release, but rather mediate mechanical stretch-induced Rho activation.




**Figure 3** Mechanical stretch activates G $\alpha_{12/13}$  and Rho through purinergic receptor. (A) Time course of Rho activation by mechanical stretch. (B) G $\alpha_{12/13}$ -mediated Rho activation by mechanical stretch. Cells were transfected with GFP, p115-RGS, and inactive mutant of p115-RGS (p115-Mut) by electroporation. (C, D) Effects of various inhibitors on Rho activation by mechanical stretch. Cells were treated with CV11974 (2.5  $\mu$ M), PD123319 (2.5  $\mu$ M), BAPTA-AM (3  $\mu$ M), nitrendipine (1  $\mu$ M), propranolol (1  $\mu$ M), prazosin (10  $\mu$ M), BQ123 (3  $\mu$ M), BQ788 (3  $\mu$ M), GsMTx4 (1  $\mu$ M), apyrase (1 U/ml), hexokinase (HK)-II (100  $\mu$ g/ml), suramin (100  $\mu$ M), PPADS (100  $\mu$ M), carboxoxolone (CBX; 20  $\mu$ M), and Pertussis toxin (PTX; 100 ng/ml for 12 h) 5 min before mechanical stretch. (E) Time courses of G $\alpha_{12}$  and G $\alpha_{13}$  activation by mechanical stretch (MS). (F) Effects of suramin on G $\alpha_{12}$  and G $\alpha_{13}$  activation. Cells were pretreated with suramin (100  $\mu$ M) 5 min before mechanical stretch. Error bars indicate s.e.m.;  $n = 4$  (A, D) and  $n = 3$  (B, C, E, F). \* indicates  $P < 0.05$  versus control.

The function of all connexins as gap junction channels or hemichannels is strongly dependent on Ca<sup>2+</sup>, but the function of pannexin-1 is independent of Ca<sup>2+</sup> (Shestopalov and Panchin, 2008). As mechanical stretch-induced Rho activation was independent of Ca<sup>2+</sup> (Figure 3C) and a low concentration of carboxoxolone (but not 1-heptanol) inhibited mechanical stretch-induced ATP release (Figure 4B), pannexin-1 appears to be a prime candidate for an ATP release channel. Pannexin-1 and pannexin-2 mRNAs, but not pannexin-3 mRNA, were expressed in mouse hearts and rat cardiomyocytes (Supplementary Figure 5). The expression of pannexin-1 mRNA was increased by pressure overload (Supplementary Figure 5A). Treatment with siRNAs for pannexin-1 induced a 50% decrease in pannexin-1 mRNA levels (Supplementary Figure 5B). The mechanical stretch-induced ATP release was decreased by about 50% in pannexin-1 siRNA-treated cardiomyocytes (Figure 4C). These results suggest that pannexin-1 mediates ATP release by mechanical stretch in rat cardiomyocytes.

#### Involvement of P2Y<sub>6</sub> receptor in mechanical stretch-induced fibrotic responses

We also examined which receptor subtype(s) is involved in mechanical stretch-induced G $\alpha_{12/13}$  activation. RT-PCR analysis showed that mouse hearts express mRNAs coding


P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub>, and P2Y<sub>12</sub> receptors (Supplementary Figure 6). Among them, mRNA levels of P2Y<sub>2</sub> and P2Y<sub>6</sub> receptors were upregulated in TAC hearts and CA-G $\alpha_{13}$  hearts. We also found that neonatal cardiomyocytes express mRNAs coding P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>6</sub>, and P2Y<sub>12</sub> receptors (data not shown). Treatment with MRS2578, a selective P2Y<sub>6</sub> receptor antagonist, suppressed mechanical stretch-induced Rho activation in a concentration-dependent manner, with an IC<sub>50</sub> value of about 0.1  $\mu$ M (Figure 5A and B). In contrast, treatment with MRS2179 (a P2Y<sub>2</sub> receptor antagonist), AR-C67719MX (a P2Y<sub>12</sub> receptor antagonist), and 8-SPT (an adenosine receptor antagonist) did not suppress mechanical stretch-induced Rho activation. As Rho is reported to regulate the expression levels of CTGF (Hahn *et al*, 2000) and periostin (Butcher *et al*, 2007), we examined the effects of P2Y receptor antagonists on the expression of these fibrogenic factors. Mechanical stretch increased expression of CTGF mRNA, which had been completely suppressed by the expression of p115-RGS, and by treatment with suramin, PPADS, and MRS2578 (Figure 5C and D). Mechanical stretch increased the expression of TGF- $\beta$ 2 mRNA but did not affect the expression of TGF- $\beta$ 1 and - $\beta$ 3 mRNAs, and the induction of TGF- $\beta$ 2 mRNA was also suppressed by suramin, PPADS, and MRS2578. In addition, mechanical stretch increased periostin proteins two-fold, which had been completely suppressed



**Figure 4** Pannexin 1 mediates mechanical stretch-induced release of nucleotides. (A) Time course of ATP release by mechanical stretch. Cells were treated with ARL67156 (50  $\mu$ M) 20 min before mechanical stretch. (B) Effects of inhibitors on the increase in extracellular ATP concentration induced by mechanical stretch. Cells were treated with suramin (100  $\mu$ M), PPADS (100  $\mu$ M), carboxoxolone (CBX), and 1-heptanol (1-Hepta) 20 min before mechanical stretch. (C) Effects of pannexin-1 siRNAs on mechanical stretch-induced ATP release. (D) UDP concentration in the culture medium from control cardiomyocytes ((-) stretch) or mechanically stretched cells for 10 min ((+) stretch). (E, F) Time courses of changes (E) and peak increases (F) in  $[Ca^{2+}]_i$  of P2Y<sub>6</sub> receptor-expressing HEK293 cells. The changes in  $[Ca^{2+}]_i$  were determined after the substitution of external solution with the culture medium (Sup.) of mechanically stretched cells. (G) Concentration-dependent maximal increases in  $[Ca^{2+}]_i$  induced by UDP in P2Y<sub>6</sub> receptor-expressing HEK293 cells. (H) Peak increases in  $[Ca^{2+}]_i$  of control (vector) and P2Y<sub>6</sub> receptor-expressing H9c2 myoblasts. The changes in  $[Ca^{2+}]_i$  were determined after the addition of the culture medium from control cardiomyocytes ((-) stretch) or mechanically stretched cells ((+) stretch) for 10 min with or without 2  $\mu$ M of carboxoxolone (+ CBX). Error bars indicate s.e.m.;  $n = 4$  (A) and  $n = 3$  (B–H). \* indicates  $P < 0.05$ , \*\* indicates  $P < 0.01$  and \*\*\* indicates  $P < 0.001$ .

by the expression of p115-RGS, and by treatment with suramin, PPADS, and MRS2578 (Figure 5E). These increases were not affected by the expression of G protein-coupled receptor kinase 2-RGS, a G $\alpha_q$ -specific RGS domain (Nishida *et al*, 2005; Onohara *et al*, 2006), nor by the treatment with P2Y<sub>1</sub> receptor antagonist (MRS2179), P2Y<sub>12</sub> receptor antagonist (AR-C67719MX), and 8-SPT (an adenosine receptor antagonist). As P2Y<sub>2</sub> receptor-selective antagonist is not

commercially available, we examined the involvement of the P2Y<sub>2</sub> receptor in mechanical stretch-induced Rho activation with siRNAs. The treatment with P2Y<sub>2</sub>-specific siRNAs decreased the mRNA by about 50% but did not suppress Rho activity (Figure 5F). In contrast, the treatment with P2Y<sub>6</sub>-specific siRNAs decreased the mRNA by about 70% and significantly suppressed mechanical stretch-induced Rho activation in cardiomyocytes. These results suggest



**Figure 5** Involvement of P2Y<sub>6</sub> receptor in mechanical stretch-induced Rho activation and expression of fibrogenic factors. (A) Effects of MRS2179 (P2Y<sub>1</sub> receptor antagonist, 10 μM), MRS2578 (P2Y<sub>6</sub> receptor antagonist, 10 μM), AR-C69931MX (P2Y<sub>12</sub> receptor antagonist, AR-C; 1 μM), and 8-(p-sulphophenyl) theophylline (8-SPT; adenosine receptor antagonist, 10 μM) on Rho activation. (B) Concentration-dependent inhibition of Rho activation by MRS2578. (C) Time courses of changes in CTGF and TGF-β1 and -β2 mRNA expressions induced by mechanical stretch. (D) Effects of inhibitors on the expression of CTGF and TGF-β2 mRNAs induced by mechanical stretch for 3 h. (E) Effects of various inhibitors on the expression of periostin induced by mechanical stretch for 24 h. The expression was plotted by the ratio to HSP90. (F) Effects of siRNAs of P2Y<sub>2</sub> and P2Y<sub>6</sub> receptors on mechanical stretch-induced Rho activation. Lower graph shows the expression levels of P2Y<sub>2</sub> and P2Y<sub>6</sub> receptor mRNAs. Error bars indicate s.e.m.; n = 3 (A, B, D, E), n = 5 (C) and n = 6 (F). \* indicates P < 0.05 versus no-stretch and # indicates P < 0.05 versus control.

that the P2Y<sub>6</sub> receptor predominantly regulates the mechanical stretch-induced activation of fibrotic signalling in cardiomyocytes.

As the P2Y<sub>6</sub> receptor is mainly activated by UDP (Vassort, 2001), and uridine nucleotides are known to be released by mechanical stretch (Lazarowski and Boucher, 2001), we also examined whether UDP is released by mechanical stretch. Mechanical stretch of cardiomyocytes increased extracellular UDP concentration three-fold (Figure 4D). In addition, treatment of P2Y<sub>6</sub> receptor-overexpressing HEK293 cells with supernatant from mechanically stretched rat cardiomyocytes significantly increased intracellular Ca<sup>2+</sup> concentrations ([Ca<sup>2+</sup>]<sub>i</sub>) (Figure 4E). The magnitude of maximal increase in [Ca<sup>2+</sup>]<sub>i</sub> induced by the supernatant was equivalent to the peak [Ca<sup>2+</sup>]<sub>i</sub> increase induced by 30 nM of extracellular UDP (Figure 4F and G). As H9c2 myofibroblasts do not express P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors, we further examined the effects of nucleotides on [Ca<sup>2+</sup>]<sub>i</sub> increase using H9c2 cells. Treatment of vector-expressing H9c2 cells with UDP, ATP, or the supernatant of stretch-activated cardiomyocytes did not show any significant increases in [Ca<sup>2+</sup>]<sub>i</sub>, but the treatment with the supernatant significantly increased [Ca<sup>2+</sup>]<sub>i</sub> in P2Y<sub>6</sub> receptor-overexpressing H9c2 cells (Figure 4H). This [Ca<sup>2+</sup>]<sub>i</sub> increase was completely suppressed by the treatment of cardiomyocytes with carbenoxolone, suggesting that pannexin-1 mediates mechanical stretch-induced UDP release. Furthermore, treatment of cardiomyocytes with 3-phenacyl-UDP, a highly

selective P2Y<sub>6</sub> receptor agonist, increased Rho activity in a concentration-dependent manner (Supplementary Figure 4H). These results suggest that extracellular UDP predominantly mediates mechanical stretch-induced P2Y<sub>6</sub> receptor activation in cardiomyocytes.

#### Inhibition of P2Y<sub>6</sub> receptors attenuates pressure overload-induced cardiac fibrosis *in vivo*


We next examined whether purinergic receptors actually participate in pressure overload-induced cardiac fibrosis *in vivo*. Treatment with MRS2578 after TAC significantly suppressed pressure overload-induced collagen deposition without affecting cardiomyocyte hypertrophy (Figure 6A–C). Treatment with MRS2578 significantly suppressed LV dysfunction induced by pressure overload (Figure 6D and E and Supplementary Table 3). Furthermore, the treatment with MRS2578 suppressed the increases in mRNA expressions of ANP, β-MHC, procollagen type 1, periostin, and TGF-β2 by pressure overload (Figure 6F). We also found that MRS2578 inhibited pressure overload-induced Rho activation and TAC-induced increases in expression of periostin, mature TGF-βs, and ACE proteins (Figure 6G and H). Furthermore, we found that treatment with suramin also suppressed pressure overload-induced collagen deposition and LV dysfunction (Supplementary Figure 7 and Supplementary Table 4). These results suggest that inhibition of P2Y<sub>6</sub> receptors

actually attenuates pressure overload-induced cardiac fibrosis and LV dysfunction.

## Discussion

Remodelling of the heart, including accumulation of ECM and an associated change in ventricular geometry, is a common feature of heart failure. In this study, we found that G $\alpha_{12/13}$  mediate cardiac fibrosis without the development of hypertrophy induced by pressure overload. We reported previously

that G $\alpha_{12/13}$  mediate agonist-induced hypertrophic responses of cardiomyocytes. However, we also found that mechanical stretch-induced increases in NFAT- and BNP-dependent transcriptional activities are not suppressed in p115-RGS-expressing myocytes (Supplementary Figure 8). These results suggest that activation of G $\alpha_{12/13}$  is not involved in mechanical stress-induced NFAT and BNP expression. G $\alpha_{12/13}$  are activated by extracellular ATP and UDP that are released by mechanical stretch. The nucleotides released through pannexin-1 hemichannels activate G $\alpha_{12/13}$ -mediated Rho



**Figure 6** Involvement of P2Y<sub>6</sub> receptors in pressure overload-induced cardiac fibrosis. Effects of MRS2578 (3 mg/kg/day, started from 3 days after TAC surgery) on TAC-induced fibrosis and hypertrophy (A–C), and LV functions (D, E). (A) Hearts (left; scale bar, 2 mm), H&E staining (center; scale bar, 30  $\mu\text{m}$ ), and picrosirius red staining (right; scale bar, 200  $\mu\text{m}$ ). (B) CSA of cardiomyocytes. (C) Results of cardiac fibrosis. (D, E) Expression of hypertrophic and fibrogenic genes. (F) Expression of hypertrophic and fibrogenic genes. (G) Effects of MRS2678 on TAC-induced Rho activation and the expression of periostin, mature TGF- $\beta$ s, ACE, and GAPDH. GAPDH was used as an internal control. Error bars indicate s.e.m.;  $n = 3$ –8 (B, C),  $n = 8$ –12 (D, E),  $n = 5$ –7 (F), and  $n = 3$  (G, H). Representative result of hearts from vehicle-sham ( $n = 3$ ), vehicle-TAC ( $n = 7$ ), and MRS-sham ( $n = 3$ ), and MRS-TAC mice ( $n = 8$ ) was shown (A). \* indicates  $P < 0.05$ , \*\* indicates  $P < 0.01$ , and \*\*\* indicates  $P < 0.001$ .

activation leading to the induction of fibrogenic factors, such as CTGF and periostin. Furthermore, inhibition of purinergic receptors attenuates the TAC-induced cardiac fibrosis and LV dysfunction. These results indicate that activation of G $\alpha_{12/13}$ -coupled purinergic receptors in cardiomyocytes by extracellular nucleotides stimulate the secretion of fibrogenic factors and trigger pressure overload-induced cardiac fibrosis (Figure 7). Purinergic receptors are classified into two families: P2X and P2Y. P2X receptors are transmitter-gated channels and consist of 7 subtypes. P2Y receptors are G protein-coupled receptors and are divided into eight subtypes. We found that the P2Y<sub>6</sub> receptor predominantly regulates mechanical stretch-induced Rho activation and the expression of fibrogenic factors in rat cardiac myocytes (Figure 5). We also found that inhibition of P2Y<sub>6</sub> receptors suppressed cardiac fibrosis and diastolic dysfunction induced by pressure overload (Figure 6). These results suggest that P2Y<sub>6</sub> receptors in cardiomyocytes have an important function in pressure overload-induced cardiac fibrosis.


It has been reported that CTGF has an important function in cardiac fibrosis. In contrast to CTGF, the function of periostin remains to be determined. Extracellular application of periostin induced re-entry of cardiomyocytes into the cell cycle, and reduced fibrosis whereas improving cardiac functions (Kühn *et al*, 2007). However, analysis of knockout and transgenic mice reveals that periostin is involved in myocardial infarction-induced fibrosis and impairment of ventricular functions (Oka *et al*, 2007; Shimazaki *et al*, 2008). They also demonstrated that pressure overload-induced hypertrophic responses and fibrosis are regulated by periostin. The present results are consistent with the findings that periostin is involved in pressure-overload-induced cardiac fibrosis.

It is interesting to note that the G $\alpha_{12/13}$ -mediated pathway regulates fibrosis, and the G $\alpha_{q/11}$ -mediated pathway regulates hypertrophy. Two different G proteins regulate two distinct responses: fibrosis and hypertrophy. Many groups using transgenic and knockout mice have reported that suppression of hypertrophy leads to the inhibition of fibrosis. However, we demonstrated that fibrosis and hypertrophy are independent processes, as revealed by expressing p115-RGS to block G $\alpha_{12/13}$  functions. Therefore, G $\alpha_{12/13}$ -mediated signalling

leading to cardiac fibrosis may turn on after hypertrophy is already developed. This speculation is supported by the finding that pannexin-1 mRNA in the heart is upregulated by pressure overload (Supplementary Figure 5A). Thus, the process of the hypertrophied heart depositing ECM proteins *in vivo* may be triggered by the release of ATP and UDP from myocytes during transition from hypertrophy to heart failure.

There are three structurally distinct TGF- $\beta$ s (Bujak and Frangogiannis, 2007). TGF- $\beta$ 1 is a prevalent isoform, and TGF- $\beta$ 2 and - $\beta$ 3 are expressed in limited tissues. As these three isoforms do not compensate for functions of other isoforms, each TGF- $\beta$  has specific and independent roles *in vivo*. Among these three isoforms, it has been reported that TGF- $\beta$ 1 mediates Ang II-induced hypertrophic responses *in vivo* (Schultz Jel *et al*, 2002). Myocardial infarction increases the expression of these three TGF- $\beta$  isoforms, which participate in inflammation at an early phase and cardiac remodelling at a later phase. We found that TGF- $\beta$ 2 mRNA was most responsive to TAC, which induces cardiac fibrosis (Figure 1). We also demonstrated that p115-RGS and the P2Y<sub>6</sub> receptor antagonist inhibit the expression of TGF- $\beta$ 2 mRNA by pressure overload (Figure 2 and Figure 6). TGF- $\beta$ 2 may be the predominant form of TGF- $\beta$  for the promotion of fibrosis in the heart.

Our results also indicate that G $\alpha_{13}$  mediates pressure overload-induced expression of ACE proteins (Figure 1 and Supplementary Figure 3). Although inhibition of ACE expression has been reported to inhibit pressure overload-induced cardiac hypertrophy in rats (Baker *et al*, 1990; Zierhut *et al*, 1991), inhibition of G $\alpha_{12/13}$ , upstream of ACE, did not suppress cardiac hypertrophy in mice (Figure 1). We do not have any data to explain this discrepancy. However, our data are consistent with the results of Xiao *et al*. (2008), which show that an increase in ACE expression does not augment pressure overload-induced cardiac hypertrophy in mice. In addition, pressure overload induces cardiac hypertrophy in angiotensinogen-knockout mice (Zou *et al*, 2004). Crowley *et al* (2006) have reported that Ang II induces cardiac hypertrophy in mice through stimulation of AT1 receptors in the kidney. It has been reported that the expression of a gain-of-function mutant of Ang II type 1A receptor in the



**Figure 7** Schema for the mechanism of cardiac fibrosis induced by pressure overload. Mechanical stretch induces release of nucleotides through pannexin-1 hemichannels (Pnx) from cardiac myocytes, which leads to stimulation of purinergic P2Y<sub>6</sub> receptors. Nucleotide-bound P2Y<sub>6</sub> receptor activates G $\alpha_{12/13}$  proteins. Activation of G $\alpha_{12/13}$  in cardiomyocytes induces the expression of fibrogenic factors, which activate cardiac fibroblasts in a paracrine manner. The activated fibroblasts produce excessive amount of collagen types I and III, leading to induction of cardiac fibrosis.

heart causes cardiac fibrosis but not hypertrophy (Billet *et al*, 2007). Thus, increase in cardiac ACE activity induced by pressure overload may not contribute to the development of cardiac hypertrophy in mice. Using rat cardiomyocytes, we found that mechanical stretch-induced activation of JNK and p38 MAPK, but not ERK, was suppressed by p115-RGS (Supplementary Figure 8). As ERK, but not JNK and p38 MAPK, participates in cardiac hypertrophy (Liang and Molkenkin, 2003), G $\alpha_{12/13}$ -mediated ACE expression may participate in mechanical stress (pressure overload)-induced hypertrophy in rats but not mice.

Cardiac fibrosis is considered one of the inflammatory responses of the heart (Brown *et al*, 2005). A variety of evidence supports the idea that extracellular nucleotides function as a mediator of inflammatory responses, such as chemotaxis and phagocytosis (Chen *et al*, 2006; Idzko *et al*, 2007; Koizumi *et al*, 2007). Our data suggest that extracellular nucleotides function as a priming factor in the development of cardiac fibrosis induced by pressure overload. It is generally thought that activation of the RAAS system and increased levels of active TGF- $\beta$  stimulate cardiac fibroblasts and induce ECM deposition, leading to perivascular fibrosis. CTGF, periostin, and TGF- $\beta$ 2 mRNAs were upregulated by pressure overload, and the increased expression of three genes were suppressed in p115-Tg mice. Furthermore, a P2Y<sub>6</sub> receptor antagonist MRS2578 suppressed the stress-induced expression of periostin and TGF- $\beta$  mRNAs *in vitro* and *in vivo*. In addition to TGF- $\beta$ , we demonstrate that CTGF and periostin are also involved in pressure overload-induced cardiac fibrosis. As G $\alpha_{12/13}$  mediate cardiac fibrosis, which is associated with pressure overload-induced hypertrophy, the development of drugs to block P2Y<sub>6</sub> receptors-G $\alpha_{12/13}$  signalling may be a novel strategy for heart failure.

The interrelationship between Ang II and TGF- $\beta$  is well established. The blockade of TGF- $\beta$  by an antibody and a mutated TGF-receptor suppressed some of Ang II-induced responses (Bujak and Frangogiannis, 2007). Therefore, it is reasonable to assume that Ang II stimulates TGF- $\beta$  expression, which leads to ECM deposition. As the blockade of the P2Y<sub>6</sub> receptor with MRS2578 suppressed the expression of ACE mRNA, and the blockade of G $\alpha_{12/13}$  suppressed the expression of TGF- $\beta$  mRNAs, ATP and UDP work as an upstream regulator of the Ang II-TGF- $\beta$  system. This also suggests that extracellular nucleotide-stimulated G $\alpha_{12/13}$  activity regulates the Ang II-TGF- $\beta$  pathway through upregulation of ACE.

It has been reported that CTGF mediates some TGF- $\beta$ -induced fibrogenic responses. Inhibition of CTGF synthesis or activity suppressed TGF- $\beta$ -induced collagen synthesis (Perbal, 2004). It is also reported that CTGF synergizes fibrogenic responses with TGF- $\beta$  by the mechanisms on the basis of the binding of CTGF to TGF- $\beta$  or transcriptional suppression of Smad7 (Ruiz-Ortega *et al*, 2007). As CTGF expression was increased in a CA-G $\alpha_{13}$ -Tg heart without affecting TGF- $\beta$  expression, extracellular ATP and UDP may directly increase the expression of CTGF through P2Y<sub>6</sub> and G $\alpha_{12/13}$ , with CTGF then promoting the production of TGF- $\beta$ . Thus, extracellular nucleotides have an important function in fibrogenic responses of the heart.

Diastolic dysfunction associated with preserved systolic function is increasingly recognized as a critical cause of heart failure. As the cardiac ECM is the major determinant of

myocardial stiffness during diastole, cardiac fibrosis contributes to diastolic dysfunction. We found that 6 weeks of TAC induces impairment of LV diastolic functions, which were attenuated by the inhibition of G $\alpha_{12/13}$  signalling or purinergic P2Y<sub>6</sub> receptors. As cardiac fibrosis associated with maladaptive hypertrophy is thought as a cause of impairment of cardiac function, purinergic receptors may be promising targets for the treatment of heart failure.

## Materials and methods

### Animals and TAC surgery

All protocols using mice and rats conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the guidelines of Kyushu University. Transgenic C57BL/6J mice expressing p115-RGS were tried to generate three times. We obtained only one line that was used in this study. Two lines of transgenic mice expressing CA-G $\alpha_{13}$  were generated (lines 1 and 5). Heterozygote of line 5 was used in this study. Age-matched male WT C57BL/6J mice were used as control. TAC surgery was performed on 8- to 10-week-old male p115-Tg and WT C57BL/6J mice. A mini-osmotic pump (Alzet) filled with saline, MRS2578, or suramin was implanted intraperitoneally 3 days after TAC into 6-week-old male C57BL/6J mice. Details can be found in Supplementary methods at *The EMBO Journal Online* (<http://embojournal.org>).

### Haemodynamic measurements and histological analyses

Transi-thoracic echocardiography was performed using ALOKA ultrasonic image analysing system (SSD-5500) equipped with 7.5 MHz imaging transducer. Blood pressure was monitored using tail-cuff system (BP-98A, Softron). LV pressure and heart rate were measured with a micromanometer catheter (Millar 1.4F, SPR 671, Millar Instruments). Histological analyses can be found in Supplementary methods at *The EMBO Journal Online* (<http://embojournal.org>).

### Isolation of cardiomyocytes and transfection

Cultures of neonatal rat cardiac myocytes and adenoviral infection were performed as described previously (Nishida *et al*, 2000). Details can be found in Supplementary methods at *The EMBO Journal Online* (<http://embojournal.org>).

### Pull-down assay and western blot analysis

Methods for pull-down assay and western blot analysis can be found in Supplementary methods at *The EMBO Journal Online* (<http://embojournal.org>).

### Measurement of extracellular nucleotides concentration

The determination of extracellular ATP concentration ( $2 \times 10^5$  cells per well) was performed using ATP Bioluminescence Assay Kit CLSII (Roche). The concentration of extracellular UDP in the supernatant of culture medium was analysed with an HPLC system (Jasco) as described previously (Koizumi *et al*, 2007). Details can be found in Supplementary methods at *The EMBO Journal Online* (<http://embojournal.org>).

### Measurement of mRNA expressions

Real-time RT-PCR was performed as described (Nagamatsu *et al*, 2006; Nishida *et al*, 2007). Sequences for PCR primers and Taqman probes were described in Supplementary information (Supplementary Table 5). The PCR primers used for expression analysis of P2Y receptors are described in Supplementary Table 6. Details can be found in Supplementary methods at *The EMBO Journal Online* (<http://embojournal.org>).

### Statistical analysis

Data were shown as means  $\pm$  s.e.m. Statistical comparisons were made with two-tailed Student's *t*-test or analysis of variance followed by Student-Newman-Keuls procedure, with significance imparted at *P*-values < 0.05.



### Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

### Acknowledgements

We thank Naoki Nishihara for TAC surgery and measurement of cardiac functions during the early stage of this study. We also thank Drs Makoto Tsuda (Kyushu University) and Isao Matsuoka

(Takasaki University of Health and Welfare) for helpful discussion and Dr Jeffery Robbins (Cincinnati Children's Hospital Medical Center) for  $\alpha$ -MHC promoter. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to MN and HK); from the Ministry of Health, Labour, and Welfare of Japan and the Japan Health Sciences Foundation (to YS); and from the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (to MN).

### References

- Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn II GW (1998) Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. *Proc Natl Acad Sci USA* **95**: 10140–10145
- Amano M, Fukata Y, Kaibuchi K (2000) Regulation and functions of Rho-associated kinase. *Exp Cell Res* **261**: 44–51
- Arai K, Maruyama Y, Nishida M, Tanabe S, Kozasa T, Mori Y, Nagao T, Kurose H (2003) Differential requirement of Gα<sub>12</sub>, Gα<sub>13</sub>, Gα<sub>q</sub>, and Gβγ for endothelin-1-induced c-Jun NH<sub>2</sub>-terminal kinase and extracellular signal-regulated kinase activation. *Mol Pharmacol* **63**: 478–488
- Baker KM, Chernin MJ, Wixson SK, Aceto JF (1990) Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. *Am J Physiol* **259**: H324–H332
- Berk BC, Fujiwara K, Lehoux S (2007) ECM remodeling in hypertensive heart disease. *J Clin Invest* **117**: 568–575
- Bhattacharyya R, Wedegaertner PB (2003) Mutation of an N-terminal acidic-rich region of p115-RhoGEF dissociates α<sub>13</sub> binding and α<sub>13</sub>-promoted plasma membrane recruitment. *FEBS Lett* **540**: 211–216
- Billet S, Bardini S, Verp S, Baudrie V, Michaud A, Conchon S, Muffat-Joly M, Escoubet B, Souil E, Hamard G, Bernstein KE, Gasc JM, Elghozi J-L, Corvol P, Clauser E (2007) Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. *J Clin Invest* **117**: 1914–1925
- Brown RD, Ambler SK, Mitchell MD, Long CS (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. *Annu Rev Pharmacol Toxicol* **45**: 657–687
- Bujak M, Frangogiannis NG (2007) The role of TGF-β signaling in myocardial infarction and cardiac remodeling. *Cardiovasc Res* **74**: 184–195
- Butcher JT, Norris RA, Hoffman S, Mjaatvedt CH, Markwald RR (2007) Periostin promotes aortic ventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. *Dev Biol* **302**: 256–266
- Burnstock G (1972) Purinergic nerves. *Pharmacol Rev* **24**: 509–581
- Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y<sub>2</sub> and A3 receptors. *Science* **314**: 1792–1795
- Christensen AP, Corey DP (2007) TRP channels in mechanosensation: direct or indirect activation? *Nat Rev Neurosci* **8**: 510–521
- Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. *J Am Coll Cardiol* **35**: 569–582
- Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM (2006) Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. *Proc Natl Acad Sci USA* **103**: 17985–17990
- Gohla A, Schultz G, Offermanns S (2000) Role for G<sub>12</sub>/G<sub>13</sub> in agonist-induced vascular smooth muscle cell contraction. *Circ Res* **87**: 221–227
- Hahn A, Heusinger-Ribeiro J, Lanz T, Zenkel S, Goppelt-Strube M (2000) Induction of connective tissue growth factor by activation of heptathelial receptors. Modulation by rho proteins and the actin cytoskeleton. *J Biol Chem* **275**: 37249–37435
- Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow Jr JC, Lambrecht BN (2007) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. *Nat Med* **13**: 913–919
- Katsuragi N, Morishita R, Nakamura N, Ochiai T, Taniyama Y, Hasegawa Y, Kawashima K, Kaneda Y, Ogihara T, Sugimura K (2004) Periostin as a novel factor responsible for ventricular dilation. *Circulation* **110**: 1806–1813
- Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K (2007) UDP acting at P2Y<sub>6</sub> receptors is a mediator of microglial phagocytosis. *Nature* **446**: 1091–1095
- Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G, Sternweis PC (1998) p115 RhoGEF, a GTPase activating protein for Gα<sub>12</sub> and Gα<sub>13</sub>. *Science* **280**: 2109–2111
- Kühn B, del Monte F, Hajjar RJ, Chang YS, Lebeche D, Arab S, Keating MT (2007) Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. *Nat Med* **13**: 962–969
- Lazarowski ER, Boucher RC (2001) UTP as an extracellular signaling molecule. *News Physiol Sci* **16**: 1–5
- Liang Q, Molkentin JD (2003) Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. *J Mol Cell Cardiol* **35**: 1385–1394
- Maruyama Y, Nishida M, Sugimoto Y, Tanabe S, Turner JH, Kozasa T, Wada T, Nagao T, Kurose H (2002) Gα<sub>12/13</sub> mediates α<sub>1</sub>-adrenergic receptor-induced cardiac hypertrophy. *Circ Res* **91**: 961–969
- Nagamatsu Y, Nishida M, Onohara N, Fukutomi M, Maruyama Y, Kobayashi H, Sato Y, Kurose H (2006) Heterotrimeric G protein Gα<sub>13</sub>-induced induction of cytokine mRNAs through two distinct pathways in cardiac fibroblasts. *J Pharmacol Sci* **101**: 144–150
- Nishida M, Maruyama Y, Tanaka R, Kontani K, Nagao T, Kurose H (2000) Gα<sub>i</sub> and Gα<sub>o</sub> are target proteins of reactive oxygen species. *Nature* **408**: 492–495
- Nishida M, Tanabe S, Maruyama Y, Mangmool S, Urayama K, Nagamatsu Y, Takagahara S, Turner JH, Kozasa T, Kobayashi H, Sato Y, Kawanishi T, Inoue R, Nagao T, Kurose H (2005) Gα<sub>12/13</sub>- and reactive oxygen species-dependent activation of c-Jun NH<sub>2</sub>-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. *J Biol Chem* **280**: 18434–18441
- Nishida M, Onohara N, Sato Y, Suda R, Ogushi M, Tanabe S, Inoue R, Mori Y, Kurose H (2007) Gα<sub>12/13</sub>-mediated up-regulation of TRPC6 negatively regulates endothelin-1-induced cardiac myofibroblast formation and collagen synthesis through nuclear factor of activated T cells activation. *J Biol Chem* **282**: 23117–23128
- Offermanns S, Mancino V, Revel JP, Simon MI (1997) Vascular system defects and impaired cell chemokinesis as a result of Gα<sub>13</sub> deficiency. *Science* **275**: 533–536
- Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW, Dorn II GW, Conway SJ, Aronow BJ, Robbins J, Molkentin JD (2007) Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. *Circ Res* **101**: 313–321
- Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, Mori Y, Nagao T, Kurose H (2006) TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. *EMBO J* **25**: 5305–5316
- Perbal B (2004) CCN proteins: multifunctional signalling regulators. *Lancet* **36**: 62–64
- Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1<sup>-/-</sup> haploinsufficient mice. *Circulation* **112**: 2959–2965

- Rosenkranz S (2004) TGF-β1 and angiotensin networking in cardiac remodeling. *Cardiovas Res* 63: 423–432
- Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-β signaling in vascular fibrosis. *Cardiovas Res* 74: 196–206
- Sadoshima J, Izumo S (1997) The cellular and molecular response of cardiac myocytes to mechanical stress. *Annu Rev Physiol* 59: 551–571
- Sawada Y, Tamada M, Dubin-Thaler BJ, Cherniavskaya O, Sakai R, Tanaka S, Sheetz MP (2006) Force sensing by mechanical extension of Src family kinase substrate p130Cas. *Cell* 127: 1015–1026
- Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T (2002) TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. *J Clin Invest* 109: 787–796
- Shestopalov VI, Panchin Y (2008) Pannexins and gap junction protein diversity. *Cell Mol Life Sci* 65: 376–394
- Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, Saga Y, Fukayama M, Sata M, Kudo A (2008) Periostin is essential for cardiac healing after acute myocardial infarction. *J Exp Med* 205: 295–303
- Simon MI, Strathmann MP, Gautam N (1991) Diversity of G proteins in signal transduction. *Science* 252: 802–808
- Suadicani SO, Vink MJ, Spray DC (2000) Slow intercellular Ca<sup>2+</sup> signaling in wild-type and Cx43-null neonatal mouse cardiac myocytes. *Am J Physiol* 279: H3076–H3088
- Vassort G (2001) Adenosine 5'-triphosphate: a P2-purinergic agonist in the myocardium. *Physiol Rev* 81: 767–806
- Wetschreck N, Rütten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S (2001) Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gα<sub>q</sub>/Gα<sub>11</sub> in cardiomyocytes. *Nat Med* 7: 1236–1240
- Xiao HD, Fuchs S, Bernstein EA, Li P, Campbell DJ, Bernstein KE (2008) Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy. *Am J Physiol* 294: H659–H667
- Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H (2008) Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. *J Cardiovas Pharmacol* 51: 61–70
- Zhang D, Gausin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD (2000) TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. *Nat Med* 6: 556–563
- Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK, Michael LH, Schneider MD, Entman ML, Schwartz RJ, Wei L (2006) Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. *FASEB J* 20: 916–925
- Zierhut W, Zimmer H-G, Gerdes AH (1991) Effect of angiotensin converting enzyme inhibition on pressure overload-induced left ventricular hypertrophy in rats. *Circ Res* 69: 609–617
- Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I (2004) Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. *Nat Cell Biol* 6: 499–506

## RESEARCH ARTICLE

## A Human Phospholamban Promoter Polymorphism in Dilated Cardiomyopathy Alters Transcriptional Regulation by Glucocorticoids

Kobra Haghghi,<sup>1</sup> Gouli Chen,<sup>1</sup> Yoji Sato,<sup>2</sup> Guo-Chang Fan,<sup>1</sup> Suiwen He,<sup>1</sup> Fotis Kolokathis,<sup>3</sup> Luke Pater,<sup>1</sup> Ioannis Paraskevaidis,<sup>3</sup> W. Keith. Jones,<sup>1</sup> Gerald W. Dorn II,<sup>4</sup> Dimitrios Th. Kremastinos,<sup>3</sup> and Evangelia G. Kranias<sup>1,5\*</sup><sup>1</sup>Department of Pharmacology and Cell Biophysics, University of Cincinnati, College of Medicine, Cincinnati, Ohio; <sup>2</sup>National Institute of Health Science, Tokyo, Japan; <sup>3</sup>Second Department of Cardiology, Medical School, Attikon General Hospital, University of Athens, Athens, Greece; <sup>4</sup>Center for Molecular Cardiovascular Research, University of Cincinnati, Cincinnati, Ohio; <sup>5</sup>Biomedical Research Foundation of the Academy of Athens, Athens, Greece

Communicated by Nancy B. Spinner

Depressed calcium handling by the sarcoplasmic reticulum (SR) Ca-ATPase and its regulator phospholamban (PLN) is a key characteristic of human and experimental heart failure. Accumulating evidence indicates that increases in the relative levels of PLN to Ca-ATPase in failing hearts and resulting inhibition of Ca sequestration during diastole, impairs contractility. Here, we identified a genetic variant in the PLN promoter region, which increases its expression and may serve as a genetic modifier in dilated cardiomyopathy (DCM). The variant AF177763.1:g.203A>C (at position -36bp relative to the PLN transcriptional start site) was found only in the heterozygous form in 1 out of 296 normal subjects and in 22 out of 381 cardiomyopathy patients (heart failure at age of 18–44 years, ejection fraction =  $22 \pm 9\%$ ). In vitro analysis, using luciferase as a reporter gene in rat neonatal cardiomyocytes, indicated that the PLN-variant increased activity by 24% compared to the wild type. Furthermore, the g.203A>C substitution altered the specific sequence of the steroid receptor for the glucocorticoid nuclear receptor (GR)/transcription factor in the PLN promoter, resulting in enhanced binding to the mutated DNA site. These findings suggest that the g.203A>C genetic variant in the human PLN promoter may contribute to depressed contractility and accelerate functional deterioration in heart failure. *Hum Mutat* 0, 1–8, 2008. © 2008 Wiley-Liss, Inc.

KEY WORDS: promoter; polymorphism; transcriptional factor; GR; GRE; cardiomyopathy; PLN; SR Ca-ATPase

## INTRODUCTION

Heart failure is a multifactorial syndrome in which intrinsic myocardial dysfunction contributes to cardiac dilation and diminished ejection performance, leading to progressive cardiac deterioration or sudden death [Richardson et al., 1996; Seidman and Seidman, 2001]. Genes causally associated with cardiomyopathy have been identified through nonbiased genetic analysis or by candidate gene studies in experimental system [Geisterfer-Lowrance et al., 1996; Franz et al., 2001]. Thus, molecular modifiers of heart failure include mutations of genes that encode cytoskeletal, sarcomeric, nuclear membrane, and calcium handling sarcoplasmic reticulum (SR) proteins. These findings have implicated pathogenic mechanisms whereby perturbation of structural integrity, contractile force dynamics, and calcium regulation within the cardiac myocyte intrinsically contribute to myocardial disease.

Abnormal calcium homeostasis is a prototypical mechanism for contractile dysfunction in failing cardiomyocytes. Depressed calcium cycling in experimental and human heart failure reflects, at least in part, impaired calcium sequestration by the SR [Chien, 2000; MacLennan and Kranias, 2003]. Calcium sequestration is mediated by a Ca-transport ATPase (SERCA2a), whose activity is

modulated by alteration in the expression and phosphorylation of phospholamban (PLN; MIM# 172405) [Luo et al., 1996; Simmerman and Jones, 1998]. In experimental models, expression levels of PLN closely correlate with basal contractile parameters and their responses to  $\beta$ -agonists [Luo et al., 1994; Kadambi et al., 1996; Brittsan et al., 2000; Dash et al., 2001]. In human heart failure, the levels of PLN are increased relative to SERCA2a, resulting in higher inhibition of the Ca-pump's Ca-affinity, which impairs relaxation [Beuckelmann et al., 1992; Meyer et al., 1995; Hasenfuss, 1998]. As a double insult, the phosphorylation status of PLN is decreased, leading to increased inhibitory function and further depression of SR Ca-cycling. Thus, PLN is a major

Received 2 May 2007; accepted revised manuscript 2 November 2007.

\*Correspondence to: Evangelia G. Kranias, Ph.D., Department of Pharmacology and Cell Biophysics, University of Cincinnati, College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0575 USA. E-mail: litsa.kranias@uc.edu

Grant sponsors: Leducq Foundation; National Institutes of Health (NIH); Grant numbers: HL-77101; HL-026057; HL-64018; HL-77101; and HL-52318.

DOI 10.1002/humu.20692

Published online in Wiley InterScience (www.interscience.wiley.com).

Ca-regulatory protein and efforts have concentrated on identifying naturally occurring mutations in the human PLN gene, which may perturb its activity and contribute to dilated cardiomyopathy (DCM). Indeed, three mutations in the coding region of the human PLN gene have been identified that are associated with familial cardiomyopathy [Haghighi et al., 2003, 2006; Schmitt et al., 2003]. However, parallel studies on genetic variants in the PLN promoter region, which may alter its expression levels, are limiting.

The PLN gene is located on human chromosome 6 [Fujii et al., 1991] and the 200bp of its 5' flanking region exhibits significant sequence homology between human, rabbit, rat, and mouse [Fujii et al., 1991; Haghighi et al., 1997; McTiernan et al., 1999a, 1999b]. Importantly, this segment of the 5' upstream region of the human PLN gene contains conserved consensus motifs for GATA, CPI/NF- $\kappa$ , M-CAT, and E-box elements, which are also found in other mammalian species [Haghighi et al., 1997; McTiernan et al., 1999a]. However, the importance of these elements in regulation of PLN gene expression under physiological and pathophysiological conditions remains uninvestigated. Indeed, most studies indicate that cardiac PLN expression levels are maintained under stress and remodeling conditions, including pressure overload, hypertrophy, and failure [Ito et al., 2001; Kogler et al., 2003; Mills et al., 2006]. A recent study reported the presence of a rare human mutation in this highly conserved PLN promoter region (A>G at -77 bp), which was associated with increased PLN (1.5-fold) expression [Minamisawa et al., 2003]. This variant was found in 1 out of 87 hypertrophic cardiomyopathy patients, suggesting a role of the PLN promoter mutant in depressed Ca cycling, leading to hypertrophy.

In this study, we sought to identify naturally occurring PLN promoter mutations in nonfamilial heart failure patients. A novel point genetic variant (A>C) at position AF177763.1:g.203A>C (at -36bp relative to the PLN transcriptional start site: -36A>C) in the 5' UTR region of the PLN gene was detected only in the heterozygous state in 22 heart failure patients and one normal subject. In vitro studies on the functional significance of this genetic variant revealed that it increases PLN expression levels by altering glucocorticoid nuclear receptor (GR)-mediated regulation of transcription.

## MATERIALS AND METHODS

### Mutation Identification

Informed consent was obtained from participating subjects. All protocols were approved by the institutional review board of the Onassis Cardiac Surgery Center (Athens, Greece) or the University of Cincinnati College of Medicine, (Cincinnati, OH). Genomic DNA was isolated either from whole blood or from paraffin blocks containing heart tissue. The genomic reference with GenBank accession number AF177763.1 was used to retrieve the PLN sequence corresponding to proximal promoter and exon 1. A 600-bp fragment of the PLN gene, containing the PLN promoter region was amplified by PCR, using 60 ng of genomic DNA and a high-fidelity *Taq* polymerase. The primers were: sense, 5'CTAAGCCTGAAGATGCG3' and antisense, 5'CCAGTAACCA GGATC3', tagged with M13 forward and reverse primer sequences, respectively. The conditions were: one cycle at 94°C for 3 min, linked to 30 cycles at 94°C for 1 min, 47°C for 1 min, and 72°C for 1 min, followed by one cycle at 94°C for 1 min, 53°C for 1 min, and 72°C for 10 min. The gel purified PLN DNA fragment was sequenced using automated dye-primer chemistry. The generated sequences were compared with the reported human PLN sequences by a computational method and the electropher-

ograms were inspected individually for confirmation. The GenBank accession number AF177763.1 was used as a reference for numbering the PLN promoter polymorphism.

### Echocardiography

Comprehensive 2D and Doppler echocardiography was performed according to the recommendations of the American Society of Echocardiography [Levy et al., 1990]. Left ventricular dimensions (interventricular septum end-diastolic thickness [IVEDT], left ventricular posterior wall end-diastolic thickness [PWEDT], left ventricular end-systolic and end-diastolic diameter [LVESD and LVEDD]) were measured with M-mode echocardiography, using the left parasternal window. Left ventricular volumes and ejection fraction (LVEF) were determined by apical two- and four-chamber views using the modified Simpson rule [Levy et al., 1990].

### Cloning of the Human PLN Gene Promoter-Reporter Constructs

A PCR-based strategy was employed using high-fidelity DNA polymerase to amplify the mutant region from human PLN genomic DNA, comprising the upstream PLN promoter. A 510-bp DNA fragment was PCR-amplified from normal and DCM genomic DNA utilizing the primers 5'-TACCTGTGTTTATTTTCTC-3' and 5'-AAGAAGAATTACCAAAGTCAGC3'. To facilitate cloning, Kpn I and Xho I sites were added to the beginning of the primers. The 510-bp fragment containing the engineered Kpn I and Xho I sites was subcloned into the pBlueScript vector (Stratagene, La Jolla, CA). The upstream PLN promoter region was verified by DNA sequence analysis. Then, the PLN promoter fragment containing either the nucleotide transition, -36A>C, or the wild type sequences of the PLN gene was digested with Sac I and Pst I, and cloned into pGL3-Basic (Promega, Madison, WI) to create the PLN promoter-luciferase reporter constructs.

About 600bp of 5' upstream of the PLN gene sequences were scanned for putative transcription factor binding sites, using public domain software (Transcription Element Search Software; www.chil.upenn.edu/tess; TFBlast of TRANSFAC 6.0; Biobase Corporation, Beverly, MA; www.gene-regulation.com/cgi-bin/pub/programs/tblast/tblast.cgi).

### Cardiomyocyte Culture, Transient Transfection, and Luciferase Assays

Ventricular myocytes were isolated from 1-day-old Sprague-Dawley rats and cultured as described [Minamisawa et al., 2003]. For promoter-reporter studies, after 24 hr incubation with serum-free medium, the myocytes were transiently cotransfected with 300 ng of each PLN luciferase test plasmid and 75 ng of pRL-TK control plasmid (Promega). The cells were harvested in Passive Lysis Buffer (Promega) 48 hr after transfection, and were stored at -80°C until processed for the luciferase assay. The cells were allowed to grow in the absence or presence of 3  $\mu$ M dexamethasone for the last 45 hr of the 48-hr incubation period. Luciferase assays were performed according to the protocol of the Dual Luciferase Assay System (Promega). Each data point represents the mean and the standard error of the mean (SEM) of seven experiments.

### Electrophoretic Mobility Shift Assays

Nuclear extracts from ventricular tissue samples were prepared as described previously [Brown et al., 2005] with modifications. Briefly, ventricular tissue was pulverized at liquid N<sub>2</sub> temperatures, homogenized at low speed in buffer containing 10 mM HEPES

(pH 9), 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 0.5 mM dithiothreitol (DTT), 25 µg/ml leupeptin, 0.2 mM sodium orthovanadate, and 0.1% (vol/vol) Triton X, then vortexed and incubated on ice for 10 min. After centrifugation (5,000g for 10 min), the pellet was suspended in solution containing 20 mM HEPES (pH 7.9), 25% (vol/vol) glycerol, 0.6 M KCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 0.5 mM phenylmethanesulfonylfluoride (PMSF), 0.5 mM DTT, 25 µg/ml leupeptin, and 0.2 mM sodium orthovanadate, and then vortexed. This suspension was incubated on ice for 40 min with rigorous vortexing every 10 min. After centrifugation (10,000g for 15 min), the supernatant was retained as a crude nuclear extract. Protein concentrations were determined using a Bio-Rad (Hercules, CA) protein assay with bovine serum albumin as a standard.

A double-stranded 20-bp oligodeoxynucleotide, containing the PLN promoter wild type (5'-CCTCCCTAG){A}{ACACTTTTTTC-3'; underlined, glucocorticoid binding element) or mutant form (5'-CCTCCCTAG){C}{ACACTTTTTTC-3'; bold, mutated nucleotide) was end-labeled using [ $\gamma$ -<sup>32</sup>P]ATP and T4 polynucleotide kinase (Promega), and was purified using a G-50 Sephadex column (Amersham Pharmacia Biotech, Piscataway, NJ). The binding reactions were performed in a final volume of 10 µl that contained 20 µg of nuclear protein, 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol (vol/vol), and 1 µg of poly(dI-dC). After a 10-min preincubation at room temperature, the labeled probe (1 × 10<sup>5</sup> cpm/reaction) was added to each reaction and the reactions were incubated for an additional 20 min at room temperature. The DNA-protein complexes were separated on 6% nondenaturing polyacrylamide gels in 1 × Tris borate-EDTA buffer. Gels were vacuum-dried and exposed to X-ray film at -20°C, using intensifying screens. Competition assays with 100-fold molar excess of unlabeled consensus oligodeoxynucleotide or control nonspecific oligodeoxynucleotide were performed to ensure that the signal was specific. The commercially available oligonucleotide containing the common glucocorticoid consensus, 5'-GACGGTACAAAATGTTCTAGG-3' (Active Motif, Carlsbad, CA) and antiglucocorticoid antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used for specific binding activity confirmation. A double-stranded 22-bp oligodeoxynucleotide (5'-AGTTGAGGGGACTTTCACAGG-3') containing a consensus nuclear factor-κB (NF-κB) binding site (underlined) was used as positive control.

## Statistics

Data are presented as mean ± SEM. Statistical analysis was performed using two-way analysis of variance (ANOVA) followed by Student-Newman-Keuls test. A P value of <0.05 was considered statistically significant. The agreement with the Hardy-Weinberg expectations (HWE) of genotype frequencies was determined using the chi-squared test based on the number of observed and expected heterozygotes and the exact test based on the number of observed and expected genotypes [Guo and Thompson, 1992].

## RESULTS

### Clinical History

A total of 381 DCM patients and 296 normal subjects without any known cardiomyopathy history were recruited from the University Hospital, Cincinnati Heart Failure/Transplant Program (Cincinnati, OH) and the Onassis Cardiac Surgery Center (Athens, Greece). The clinical characteristics and the demographic data for the DCM populations are summarized in Table 1.

TABLE 1. Clinical Characteristics of the United States and Greek DCM Patients With Heart Failure

	Ethnicity	
	United States	Greek
n	163	218
Age (years)	44.95 ± 3.3	40 ± 6.2
Gender (%)		
Male	72	82
Female	28	18
Etiology (%)		
Dilated cardiomyopathy	94.27	100
Ischemic cardiomyopathy	5.76	—
Functional class (% NYHA III/IV)	67.2	70.6
LVEF (%)	23.6 ± 8	26.4 ± 6

DCM, dilated cardiomyopathy; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association Classification.

Comorbid conditions in the cohorts included: hypertension (8%), diabetes (6%), hypercholesterolemia (12%), and atrial fibrillation (12%). The medications used by the DCM patients were angiotensin-converting enzyme (ACE) inhibitors (97%), diuretics (94%), digoxin (98%), beta blockers (75%), Ca-channel blockers (12%), and antiarrhythmics (45%).

### Identification of a Genetic Variant in the Human PLN Promoter Region

In the initial discovery study, the PLN gene promoter region 600 bp upstream from the transcriptional start site [McTiernan et al., 1999a] was sequenced in 40 unrelated Greek DCM patients. The sequencing of this region identified a single nucleotide transition from A>C at position AF177763.1:g.203A>C (at -36bp relative to the PLN transcriptional start site: -36A>C) (Fig. 1A). We subsequently screened an additional 178 Greek DCM patients to determine the frequency of this PLN genetic variant. The -36A>C substitution was found in another 15 patients (16/218 total) and it was only present in the heterozygous form, reflecting an allelic frequency of 3.66% in the Greek DCM population. To confirm the presence of this novel PLN promoter variant in a different heart failure population, 163 Caucasian DCM patients (University Hospital, Cincinnati Heart Failure/Transplant Program, University of Cincinnati, OH) were also screened. The -36A>C variant was found in the heterozygous form in six patients, reflecting an allelic frequency of 1.84%. The characteristics of the patients with the identified transition in the PLN gene in the two cohorts were similar (Table 2). The PLN -36A>C variant carriers presented with heart failure symptoms and were diagnosed with cardiomyopathy at ages ranging from 18 to 44 years. Echocardiography studies indicated severe left ventricular dilatation and systolic dysfunction (e.g., ejection fraction of 22 ± 9%). Their symptoms remained under control with drug treatments. However, some patients' symptoms progressively deteriorated (New York Heart Association [NYHA] Classification, NYHA class III), leading to the death of one patient at the age of 48 years and heart transplantation in another patient at the age of 46 years. The promoter variant -36A>C was found in only 1 normal control subject out of 296 screened. There were no departures from Hardy-Weinberg equilibrium for allelic frequencies in either DCM or control populations.

The promoter region of the human PLN gene, containing the genetic variant is a highly conserved region among species (Fig. 1B) [McTiernan et al., 1999a]. Therefore, it was hypothesized that this change in nucleotide sequence might alter PLN




FIGURE 1. Genomic DNA sequence analysis of the PLN promoter region. **A:** Partial nucleotide sequences of the PLN promoter region in normal subjects and DCM patients heterozygous for the AF177763.1:g.203A>C (at -36bp from transcriptional start site: -36A>C) substitution. **B:** Sequence comparison of the proximal mammalian PLN promoter sequences was performed by the FASTA program ([http://fasta.bioch.virginia.edu/fasta\\_www2/fasta\\_list2.shtml](http://fasta.bioch.virginia.edu/fasta_www2/fasta_list2.shtml)) (GenBank reference sequence numbers AF177763.1, AF037348.1, L03381.1, and M63600.1). The numbers correspond to human nucleotides upstream of exon 1 (transcription start site, underlined). The position of the A>C transition (boxed) is indicated. Gaps are shown by dash. Polymorphism numbering is based on using the GenBank accession number AF177763.1 for human PLN sequence corresponding to proximal promoter and exon 1 and the transcription start site as a reference. [Color figure can be viewed in the online issue, which is available at <http://www.interscience.wiley.com>.]

TABLE 2. Clinical Characteristics of Dilated Cardiomyopathy Patients With the -36A>C Substitution in the PLN Gene\*

	Wild-type allele	Mutant allele
n	359	22
Age (years)	42 ± 3.1	40 ± 6
Etiology (%)		
Dilated cardiomyopathy	94.27	100
Functional class (% NYHA III/IV)	67.2	66.66
LVEF (%)	24.5 ± 8	22 ± 9

\*Polymorphism numbering is based on using the GenBank accession number AF177763.1 for human PLN sequence, corresponding to proximal promoter and exon 1 as a reference.

DCM, dilated cardiomyopathy; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association Classification.


promoter activity and consequently its regulation of SERCA2a, and thus contribute to the pathophysiology of heart failure.

### In Vitro Assays of PLN Promoter Activity


To determine the potential functional importance of the identified genetic variation on PLN transcriptional regulation, we generated reporter constructs that expressed luciferase under the control of the putative promoter sequences from the human PLN gene. When neonatal rat cardiomyocytes were transiently transfected with luciferase reporters under the control of wild-type (PLN-WT) or "mutant" PLN (PLN-MT) promoters, the -36A>C transition resulted in a significant increase of 24% in transcriptional activity, compared to the wild-type promoter (Fig. 2A). To examine whether the -36A>C point transition in the PLN gene may alter regulation by any of the sequence-specific DNA-binding proteins, such as transcription factors, we performed a computer sequence search for putative regulatory binding sites.

We identified a potential sequence for the glucocorticoid response element (GRE) within the mouse PLN promoter (Fig. 2B). Our DNA scanning revealed that the -36A>C substitution was within the putative glucocorticoid receptor binding site of the PLN promoter gene. To further investigate the regulation of PLN gene expression by the glucocorticoid response element, the luciferase reporter constructs of PLN-WT and PLN-MT were transiently transfected into rat neonatal cardiac cells in the absence or presence of dexamethasone. The induced luciferase activity of PLN-WT was significantly increased when dexamethasone was present, while there was no effect of dexamethasone on the PLN-MT, compared to basal levels (Fig. 2A). The lack of luciferase activity induction in PLN-MT following stimulation of transfected cells by dexamethasone may indicate that the genetic variant abolished the direct or indirect mediation of the dexamethasone-mediated enhancement of the reporter gene activity.

To further examine the functional significance of the -36A>C PLN promoter variant, gel mobility shift assays were employed. Using nuclear extracts from mouse heart, the binding assays showed that both synthetic WT (Fig. 3; lanes 13 and 14) and MT (Fig. 3; lanes 11 and 12) oligonucleotides were able to form a DNA-protein complex, indicating transcription factor binding. However, stronger binding was observed with the PLN-MT oligonucleotide, demonstrating that this sequence has a higher affinity for transcription factor binding. Binding was completely blocked in the presence of 100-fold excess of the cold-labeled WT (Fig. 3; lanes 3 and 4) or MT oligonucleotide (Fig. 3; lanes 5 and 6), used as specific competitors. Nuclear lysate was used as a negative control and it did not form any complexes in the presence of either synthetic WT or MT oligonucleotide (Fig. 3; lanes 7-10). However, an oligonucleotide containing a consensus NF-κB binding site, used as a positive control for nuclear lysate activity, yielded DNA-protein complexes in the lysates. These findings



**FIGURE 2.** Effect of the -36A > C genetic variant on human PLN promoter activity. **A:** Rat neonatal cardiomyocytes were transiently transfected with a luciferase expression vector driven by PLN-WT or PLN-MT (-36A > C) promoters, and were cultured in the absence (left) or presence (right) of 3  $\mu$ M dexamethasone (Dex) for 45 hr. Transcriptional activity of the promoters was defined as a ratio of firefly luciferase activity to Renilla luciferase activity in the same cells, and normalized to the mean basal transcriptional activity of the promoter-less pGL3-basic vector. **B:** Sequence alignment of the normal and mutant human PLN upstream promoter regions. The relative positions of the promoter starting site (-1) and of the potential regulatory sequences (underlined) are indicated. The values are expressed as means  $\pm$  SEM ( $n = 7$ ). \* $P < 0.05$  vs. PLN-WT without Dex (two-way ANOVA and Student-Neuman-Keuls test). Polymorphism numbering is based on using the GenBank accession number AF177763.1 for human PLN sequence corresponding to proximal promoter and exon 1 as a reference.



**FIGURE 3.** Electrophoretic mobility gel shift assay of wild-type and genetically-altered glucocorticoid elements in the PLN promoter sequences. Electrophoretic mobility gel shift assays were used to determine DNA-protein complex formation using nuclear extracts from mouse hearts. NF- $\kappa$ B was used as a positive technical control (lanes 1 and 2); nonlabeled wild-type (PLN-WT, lanes 3 and 4) and altered (PLN-MT, lanes 5 and 6) were used as specific competitors; and nuclear lysate as a negative control (lanes 7-10); PLN-MT oligonucleotide (lanes 11 and 12) and PLN-WT oligonucleotide (lanes 13 and 14). Duplicate samples were assayed for each treatment.

suggest that the quality of the nuclear lysates and the binding conditions were appropriate (Fig. 3; lanes 1 and 2).

To verify whether the binding activity from heart nuclear extracts reflects a specific interaction between the GR with the PLN-WT and PLN-MT probes, as predicted based upon computer searches, we employed a commercially available oligonucleotide, containing a known consensus GRE sequence. This oligonucleotide was used in DNA binding and competition studies, designed to assess specificity of our DNA-protein complexes. The GRE

consensus oligonucleotide displayed a strong DNA-protein binding complex in nuclear extracts (Fig. 4; lane 3). Furthermore, this commercially available oligonucleotide could completely block DNA-protein complex formation with PLN-WT, PLN-MT, and the GRE oligonucleotide in the nuclear extracts (100-fold excess; Fig. 4; lanes 4-6). The consensus GRE containing oligonucleotide and the PLN promoter-derived sequences (PLN-WT and PLN-MT) demonstrated identical migration of the DNA-protein complexes (Figs. 3 and 4). It was interesting to note that the




FIGURE 4. Electrophoretic mobility gel shift assay of the PLN wild-type and genetically-altered glucocorticoid element specificity in the presence of common glucocorticoid consensus. Consensus glucocorticoid receptor element (GRE), PLN-WT, and PLN-MT motifs were used to examine binding specificity in cardiac nuclear extracts from wild-type mice. Lanes 1-3: cardiac nuclear extracts reacted with radiolabeled oligonucleotides of PLN-WT, PLN-MT, and consensus GRE sequences. Lanes 4-6: consensus GRE oligonucleotides were used as specific competitor ( $100 \times$  unlabeled GRE oligonucleotides). Lanes 7-9 and lanes 10-12: PLN-WT and PLN-MT oligonucleotides were used as competitors ( $100 \times$  unlabeled oligonucleotide), respectively.

PLN-WT or PLN-MT oligonucleotides could not completely compete with the common glucocorticoid consensus (Fig. 4; lanes 9 and 12). Taken together, these results indicate that the GR binds specifically to the PLN-WT and PLN-MT promoter sequences, albeit at lower affinity than the consensus GRE employed.

## DISCUSSION

In this study, we identified a novel variant ( $-36A > C$ ) in the human PLN promoter region in 22 heart failure patients and one normal subject, which appears to enhance promoter activity and alter the GR receptor binding element. Importantly, this PLN promoter variant was identified in two heart failure populations. The allelic frequencies in two ethnic populations and in controls were in Hardy-Weinberg equilibrium, indicating that this genetic variant is heritable and a combination of the  $-36A > C$  PLN variant with other genetic and environmental modifiers may contribute to the time course of the disease in the patients. The identified nucleotide substitution is in close proximity to the putative TATA ( $5'$ -TCATAA- $3'$ ) boxes at position  $-48$  to  $-53$  in an evolutionarily conserved PLN gene region between species, and may play a significant role in regulating PLN gene expression. Indeed, *in vitro* studies of this genetic variant indicated that it may increase PLN expression levels and consequently, depress SR Ca cycling associated with cardiomyopathy. The functional significance of increased PLN levels in cardiac muscle has previously been demonstrated through the generation and characterization of transgenic mouse models [Kadambi et al., 1996; Dash et al., 2001]. Consistent with findings in transgenic mice, an increase in the apparent stoichiometry of PLN to SERCA2a, as a result of the PLN promoter genetic variant, may contribute to the depressed Ca cycling and deterioration of cardiac function.

Recently, there has been a considerable upsurge of interest in the influence of *cis*-acting genetic variations on gene transcription. Furthermore, these mutations and polymorphisms, found in various gene promoter regions, have been reported to affect gene

expression and impact function [Collins et al., 2003; Hudson, 2003; Buckland et al., 2004; Guy et al., 2004; Schulz et al., 2006]. Importantly, the PLN promoter variant ( $A > C$ , underlined below), identified herein, was within a novel consensus sequence segment that matched a glucocorticoid receptor-binding site ( $5'$ -AGAA-GA- $3'$ ). Previous studies have shown that thyroid hormone and glucocorticoids regulate the expression of several genes, including calcium cycling proteins [Kiss et al., 1994, 1998; Smith and Smith, 1994; Brittsan et al., 1999; Muangmingsuk et al., 2000]. Thyroid hormone was reported to mediate changes in PLN protein levels [Kiss et al., 1994, 1998; Brittsan et al., 1999] possibly through interaction with thyroid hormone elements residing in the PLN promoter region. Glucocorticoids downregulate Na-Ca exchanger mRNA levels and activity in aortic myocytes [Smith and Smith, 1994], while they increase expression of alpha-myosin heavy chain (MHC) and decreased expression of beta-MHC in neonatal rat cardiomyocytes [Muangmingsuk et al., 2000]. These changes suggest that, similar to thyroid hormone-mediated transcriptional activation, the glucocorticoid effects may also be mediated in part through transcriptional mechanisms. Indeed, the level of PLN transcripts was significantly decreased, when rat neonatal cardiomyocytes were treated with cytokines (interleukin [IL]-1 $\beta$ , tumor necrosis factor [TNF]) [McTiernan et al., 1997], while dexamethasone significantly elevated the levels of PLN transcripts [McTiernan et al., 1997], indicating the direct effects of dexamethasone on PLN gene regulation. In this report, similar results were obtained with dexamethasone induction of PLN-WT promoter expression. In contrast, dexamethasone did not increase the luciferase transcriptional activity of the PLN-MT promoter, suggesting that the  $-36A > C$  substitution may have abolished the interaction site for glucocorticoid receptor elements in the PLN gene.

The role of transacting elements in the transcriptional activity of the PLN gene remains poorly understood and the nuclear proteins involved in the regulation of the gene through binding to these elements are unknown. Our previous studies on



characterization of the mouse PLN promoter indicated that 200 bp proximal to the transcriptional initiation site is sufficient for moderate (40%) expression of PLN levels [Haghighi et al., 1997]. The dexamethasone-responsive PLN gene sequences are located within the 200-bp proximal promoter region of the mouse and human PLN gene, which are highly conserved between species [Haghighi et al., 1997; McTiernan et al., 1999a]. Increased luciferase activity in the promoter-reporter studies suggest that GREs within this region may contribute to the modulation of transcriptional regulation via DNA-protein interactions of the PLN gene as further supported by electrophoretic mobility gel shift assay studies. Obviously, the limitation of this study is that the upregulation of the PLN promoter activity presented here is primarily from *in vitro* studies; *in vivo* relevance of these finding could not be performed due to lack of cardiac biopsies from affected individuals.

The glucocorticoid receptor is a ligand-dependent transcription factor with both hormone and DNA binding domains, affecting the transcription of specific genes [Schoneveld et al., 2004]. Specifically, glucocorticoid hormones are the major mediators of systemic stress responses [Brent et al., 1991] and it has been suggested that they may regulate SR function and cellular calcium homeostasis in the myocardium [Rao et al., 2001; Aoyama et al., 2005]. The possible mechanisms may involve modulation of PLN phosphorylation through Ca/calmodulin-dependent protein kinase II (CaM kinase II) [Rao et al., 2001]. Interestingly, the CaM kinase II dependent phosphorylation site of PLN, Thr17, has been implicated in stress responses of the cardiomyocytes [Hagemann et al., 2000; Zhao et al., 2004]. Therefore, under stress conditions, GR modulation of PLN activity and/or expression levels may influence SR Ca cycling and myocardial function, which may be beneficial during early cardiac remodeling but deleterious under pathophysiological conditions. However, the abolished PLN GRE site by the -36A>C genetic variant eliminates the GR-mediated regulation, resulting in chronic increases in PLN expression levels and inhibition of SERCA activity, which may accelerate deterioration of function in DCM.

#### ACKNOWLEDGMENTS

We thank all the patients for their participation and we thank the physicians in the Department of Medicine at the University of Cincinnati, Cincinnati, OH, and the Onassis Cardiac Surgery Center in Athens, Greece, for their collaboration in this study. This research was supported by grants from the NIH (HL-77101 [to E.G.K. and G.W.D.]; HL-026057 [to E.G.K.]; HL-64018 [to E.G.K.]; and HL-52318 [to G.W.D.]) and from the Leducq Foundation (to E.G.K. and G.W.D.).

#### REFERENCES

Aoyama T, Matsui T, Novikov M, Park J, Hemmings B, Rosenzweig A. 2005. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. *Circulation* 111: 1652-1659.

Beuckelmann DJ, Nabauer M, Erdmann E. 1992. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. *Circulation* 85:1046-1055.

Brent GA, Moore DD, Larsen PR. 1991. Thyroid hormone regulation of gene expression. *Annu Rev Physiol* 53:17-35.

Brittsan AG, Kiss E, Edes I, Grupp IL, Grupp G, Kranias EG. 1999. The effect of isoproterenol on phospholamban-deficient mouse hearts with altered thyroid conditions. *J Mol Cell Cardiol* 31:1725-1737.

Brittsan AG, Carr AN, Schmidt AG, Kranias EG. 2000. Maximal inhibition of SERCA2 Ca affinity by phospholamban in transgenic hearts

overexpressing a non-phosphorylatable form of phospholamban. *J Biol Chem* 275:12129-12135.

Brown M, McGuinness M, Wright T, Ren X, Wang Y, Boivin GP, Hahn H, Feldman AM, Jones WK. 2005. Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli *in vivo*. *Am J Physiol Heart Circ Physiol* 289:H466-H476.

Buckland PR, Coleman SL, Hoogendoorn B, Guy C, Smith SK, O'Donovan MCA. 2004. High proportion of chromosome 21 promoter polymorphisms influences transcriptional activity. *Gene Expr* 11: 233-239.

Chien KR. 2000. Genomic circuits and the integrative biology of cardiac diseases. *Nature* 407:227-232.

Collins FS, Green ED, Guttmacher AE, Guyer MS. 2003. A vision for the future of genomics research. *Nature* 422:835-847.

Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW II, Kranias EG. 2001. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. *Circulation* 103:889-896.

Franz WM, Muller OJ, Katus HA. 2001. Cardiomyopathies: from genetics to the prospect of treatment. *Lancet* 358:1627-1637.

Fujii J, Zaran-Herzberg A, Willard HF, Tada M, MacLennan DH. 1991. Structure of the rabbit phospholamban gene, cloning of the human cDNA, and assignment of the gene to human chromosome 6. *J Biol Chem* 266:11669-11675.

Geisterfer-Lowrance AA, Christie M, Conner DA, Ingwall JS, Schoen FJ, Seidman CE, Seidman JG. 1996. A mouse model of familial hypertrophic cardiomyopathy. *Science* 272:731-734.

Guo SW, Thompson EA. 1992. Performing the exact test of Hardy-Weinberg proportions for multiple alleles. *Biometrics* 48:361-372.

Guy CA, Hoogendoorn B, Smith SK, Coleman S, O'Donovan MC, Buckland PR. 2004. Promoter polymorphisms in glutathione-S-transferase genes affect transcription. *Pharmacogenetics* 14:45-51.

Hagemann D, Kuschel M, Kuramochi T, Zhu W, Cheng H, Xiao RP. 2000. Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes. *J Biol Chem* 275:22532-22536.

Haghighi K, Kadambi VJ, Koss KL, Luo W, Harrer JM, Ponniah S, Zhou Z, Kranias EG. 1997. *In vitro* and *in vivo* promoter analyses of the mouse phospholamban gene. *Gene* 203:199-207.

Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW II, MacLennan DH, Kremastinos DT, Kranias EG. 2003. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. *J Clin Invest* 111:869-876.

Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW II, MacLennan DH, Kremastinos DT, Kranias EG. 2006. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. *Proc Natl Acad Sci USA* 103:1388-1393.

Hasenfuss G. 1998. Alterations of calcium-regulatory proteins in heart failure. *Cardiovasc Res* 37:279-289.

Hudson TJ. 2003. Wanted: regulatory SNPs. *Nat Genet* 33:439-440.

Ito K, Yan X, Feng X, Manning WJ, Dillmann WH, Lorell BH. 2001. Transgenic expression of sarcoplasmic reticulum Ca-ATPase modifies the transition from hypertrophy to early heart failure. *Circ Res* 89:422-429.

Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW II, Walsh RA, Kranias EG. 1996. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. *J Clin Invest* 97:533-539.

Kiss E, Jakab G, Kranias EG, Edes I. 1994. Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca transport and myocardial relaxation. *Circ Res* 75:245-251.

Kiss E, Brittsan AG, Edes I, Grupp IL, Grupp G, Kranias EG. 1998. Thyroid hormone-induced alterations in phospholamban-deficient mouse hearts. *Circ Res* 83:608-613.

- Kogler H, Hartmann O, Leineweber K, Nguyen P, Schott P, Brodde OE, Hasenfuss G. 2003. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. *Circ Res* 93:230-237.
- Levy D, Garrison RJ, Savage DD, Kannel WB, Castell WP. 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 322:1561-1566.
- Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG. 1994. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. *Circ Res* 75:401-409.
- Luo W, Wolska BM, Grupp IL, Harrer JM, Haghghi K, Ferguson DG, Slack JP, Grupp G, Doetschman T, Solaro RJ, Kranias EG. 1996. Phospholamban gene dosage effects in the mammalian heart. *Circ Res* 78:839-847.
- MacLennan DH, Kranias EG. 2003. Phospholamban: a crucial regulator of cardiac contractility. *Nat Rev Mol Cell Biol* 4:566-577.
- McTiernan CF, Bonnie H Lemster, Frye C, Brooks S, Combes A, Feldman AM. 1997. Interleukin-1 $\beta$  inhibits phospholamban gene expression in cultured cardiomyocytes. *Circ Res* 81:493-503.
- McTiernan CF, Frye CS, Lemster BH, Kinder EA, Ogletree-Hughes ML, Moravec CS, Feldman AM. 1999a. The human phospholamban gene: structure and expression. *Mol Cell Cardiol* 31:679-692.
- McTiernan CF, Lemster BH, Frye CS, Johns DC, Feldman AM. 1999b. Characterization of proximal transcription regulatory elements in the rat phospholamban promoter. *J Mol Cell Cardiol* 31:2137-2153.
- Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. 1995. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. *Circulation* 92:778-784.
- Mills GD, Kubo H, Harris DM, Berretta RM, Piacentino V III, Houser SR. 2006. Phosphorylation of phospholamban at threonine-17 reduces cardiac adrenergic contractile responsiveness in chronic pressure overload-induced hypertrophy. *Am J Physiol Heart Circ Physiol* 291:H61-H70.
- Minamisawa S, Sato Y, Tatsuguchi Y, Fujino T, Imamura S, Uetsuka Y, Nakazawa M, Matsuoka R. 2003. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. *Biochem Biophys Res Commun* 304:1-4.
- Muangmingsuk S, Ingram P, Gupta MP, Arcilla RA, Gupta M. 2000. Dexamethasone induced cardiac hypertrophy in newborn rats is accompanied by changes in myosin heavy chain phenotype and gene transcription. *Mol Cell Biochem* 209:165-173.
- Rao MK, Xu A, Narayanan N. 2001. Glucocorticoid modulation of protein phosphorylation and sarcoplasmic reticulum function in rat myocardium. *Am J Physiol Heart Circ Physiol* 281:H325-H333.
- Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyrfas I, Martin I, Nordet P. 1996. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. *Circulation* 93:841-842.
- Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE. 2003. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. *Science* 299:1410-1413.
- Schoneveld OJ, Gaemers IC, Lamers WH. 2004. Mechanisms of glucocorticoid signalling. *Biochim Biophys Acta* 1680:114-128.
- Schulz V, Hendig D, Henjakovic M, Szliska C, Kleesiek K, Gotting C. 2006. Mutational analysis of the ABCC6 gene and the proximal ABCC6 gene promoter in German patients with pseudoxanthoma elasticum (PXE). *Hum Mutat* 27:831-844.
- Seidman JG, Seidman C. 2001. Genetic basis for cardiomyopathy from mutation identification to mechanistic paradigms. *Cell* 104:557-567.
- Simmerman HK, Jones LR. 1998. Phospholamban: protein structure, mechanism of action, and role in cardiac function. *Physiol Rev* 78:921-947.
- Smith L, Smith JB. 1994. Regulation of sodium-calcium exchanger by glucocorticoid and growth factor in vascular smooth muscle. *J Biol Chem* 269:27527-27531.
- Zhao W, Uehara Y, Chu G, Song Q, Qian J, Young K, Kranias EG. 2004. Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. *J Mol Cell Cardiol* 37:607-612.

## Alteration of *N*-glycosylation in the kidney in a mouse model of systemic lupus erythematosus: relative quantification of *N*-glycans using an isotope-tagging method

Noritaka Hashii,<sup>1,2</sup> Nana Kawasaki,<sup>1,2</sup> Satsuki Itoh,<sup>1</sup> Yukari Nakajima,<sup>1,2</sup> Toru Kawanishi<sup>1</sup> and Teruhide Yamaguchi<sup>1</sup>

<sup>1</sup>Division of Biological Chemistry and Biologics, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan, and <sup>2</sup>Core Research for Evolutional Science and Technology (CREST) of the Japan Science and Technology Agency (JST), Kawaguchi City, Saitama, Japan

doi:10.1111/j.1365-2567.2008.02898.x

Received 19 March 2008; revised 28 May 2008; accepted 2 June 2008.

Correspondence: N. Kawasaki, Division of Biological Chemistry and Biologics, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Email: nana@nih.go.jp

Senior author: Teruhide Yamaguchi. email: yamaguch@nih.go.jp

### Introduction

Glycosylation is one of the most common post-translational modifications<sup>1,2</sup> and contributes to many biological processes, including protein folding, secretion, embryonic development and cell-cell interactions.<sup>3</sup> Alteration of glycosylation is associated with several diseases, including inflammatory responses and malignancies;<sup>4-6</sup> for instance, significant increases in fucosylation and branching are found in ovarian cancer and lung cancer.<sup>7</sup> Additionally, the carbohydrate structure changes from type I glycans (Gal $\beta$ 1-3GlcNAc) to type II glycans (Gal $\beta$ 1-4GalNAc) in

### Summary

Changes in the glycan structures of some glycoproteins have been observed in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. A deficiency of  $\alpha$ -mannosidase II, which is associated with branching in *N*-glycans, has been found to induce SLE-like glomerular nephritis in a mouse model. These findings suggest that the alteration of the glycosylation has some link with the development of SLE. An analysis of glycan alteration in the disordered tissues in SLE may lead to the development of improved diagnostic methods and may help to clarify the carbohydrate-related pathogenic mechanism of inflammation in SLE. In this study, a comprehensive and differential analysis of *N*-glycans in kidneys from SLE-model mice and control mice was performed by using the quantitative glycan profiling method that we have developed previously. In this method, a mixture of deuterium-labelled *N*-glycans from the kidneys of SLE-model mice and non-labelled *N*-glycans from kidneys of control mice was analysed by liquid chromatography/mass spectrometry. It was revealed that the low-molecular-mass glycans with simple structures, including agalactobiantennary and paucimannose-type oligosaccharides, markedly increased in the SLE-model mouse. On the other hand, fucosylated and galactosylated complex type glycans with high branching were decreased in the SLE-model mouse. These results suggest that the changes occurring in the *N*-glycan synthesis pathway may cause the aberrant glycosylations on not only specific glycoproteins but also on most of the glycoproteins in the SLE-model mouse. The changes in glycosylation might be involved in autoimmune pathogenesis in the model mouse kidney.

**Keywords:** isotope-tagging method; liquid chromatography/multiple-stage mass spectrometry; systemic lupus erythematosus

carcinoembryonic antigen in colon cancer.<sup>8</sup> Furthermore, an increase in biantennary oligosaccharides lacking galactose (Gal) was found on immunoglobulin G (IgG) in systemic lupus erythematosus (SLE) and rheumatoid arthritis,<sup>9-11</sup> and agalactoglycans are used for the early diagnosis of rheumatoid arthritis.<sup>12</sup>

Systemic lupus erythematosus is an autoimmune disease characterized as chronic and as a systemic disease, with symptoms such as kidney failure, arthritis and erythema. In addition to the known changes in glycosylation on IgG, there have been several reports on the association between glycosylation and inflammation in SLE and rheumatoid

arthritis.<sup>13–15</sup> A deficiency of  $\alpha$ -mannosidase II ( $\alpha$ M-II), which is associated with branching in *N*-glycans, has been found to induce human SLE-like glomerular nephritis in a mouse model.<sup>16</sup> Green *et al.* reported that branching structures of *N*-glycan in mammals are involved in protection against immune responses in autoimmune disease pathogenesis.<sup>17</sup> Although there is no direct evidence that alteration of glycosylation is the upstream event in the pathogenesis of SLE, these findings suggest that changes in the glycan structure may be involved in the inflammatory-related autoimmune disorder. Glycosylation analysis may lead to the development of improved diagnostic methods and may help to clarify the carbohydrate-related pathogenic mechanism of inflammation in SLE.

Mass spectrometry (MS) and liquid chromatography/mass spectrometry (LC/MS) are the most prevalent strategies for identifying disease-related glycans in glycomics.<sup>18–20</sup> Aberrant glycosylations in some disease samples have been found by comparing mass spectra or chromatograms between normal and disease samples; however, because of the tremendous heterogeneities of the sugar moiety in glycoprotein as well as the low reproducibility of LC/MS, accurate quantitative analysis is difficult using MS and LC/MS alone. To overcome these problems, we previously developed the stable isotope-tagging method for the quantitative profiling of glycans using 2-aminopyridine (AP).<sup>21</sup> After the glycans are released from sample and the reference glycoproteins are derivatized to pyridyl amino ( $d_0$ -PA) glycans and to tetra-deuterium-labelled pyridyl amino ( $d_4$ -PA) glycans, respectively, a mixture of both  $d_0$ -PA and  $d_4$ -PA glycans was subjected to LC/MS, and the levels of individual glycans were calculated from the intensity ratios of  $d_0$ -glycan and  $d_4$ -glycan molecular ions (Fig. 1a). Recently, alternative isotope-tagging methods using deuterium-labelled compounds, such as 2-aminobenzoic acid its derivatives, and permethylation, have been proposed by other groups.<sup>22–24</sup> All of these studies prove the utility of isotope-tagging methods for the quantitative analysis of glycosylation.

In the present study, we used the isotope-tagging method to analyse changes in *N*-glycosylation in the disordered kidney in an SLE mouse model. We used an MRL/MpJ-lpr/lpr (MRL-lpr) mouse which lacks the Fas antigen gene.<sup>25–27</sup> The MRL-lpr mouse is known to naturally develop SLE-like glomerular nephritis and is widely used in SLE studies. MRL/MpJ+/+ (MRL+/+) mice were used as controls.

## Materials and methods

### Materials

The kidneys of the SLE-model mice (MRL-lpr) and control mice (MRL+/+) ( $n = 3$ ) were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Thermolysin (EC 3.4.24.27), originating from *Bacillus thermoproteolyticus*




Figure 1. (a) Quantitative glycan profiling using the stable isotope-tagging method and liquid chromatography/mass spectrometry (LC/MS). (i) sample = control, (ii) sample > control, (iii) sample < control. (b) Total ion chromatogram obtained by a single scan ( $m/z$  700–2000) of the  $d_0$ -glycan and  $d_4$ -glycan mixture.

Rokko, was purchased from Daiwa Kasei (Shiga, Japan). Glycopeptidase A (PNGase A) was obtained from Seikagaku Kogyo Corporation (Tokyo, Japan). Non-deuterium-labelled 2-aminopyridine ( $d_0$ -AP) and deuterium-labelled 2-aminopyridine ( $d_4$ -AP) were purchased from Takara Bio (Otsu, Japan) and Cambridge Isotope Laboratories (Andover, MA), respectively.

### Sample preparation

Mouse kidneys were filtered using a cell strainer (70  $\mu$ m; BD Biosciences, San Jose, CA) and contaminating blood cells in the kidney cells were burst in 140 mM  $\text{NH}_4\text{Cl}$ -Tris buffer (pH 7.2). The surviving kidney cells were washed three times with phosphate-buffered saline containing a mixture of protease inhibitors (Wako, Tokyo, Japan) and dissolved in guanidine-HCl buffer (8 M guanidine-HCl, 0.5 M Tris-HCl, pH 8.6) containing a mixture of protease inhibitors by vortexing at 4°C. The protein concentration was measured using a 2-D Quant Kit (GE Healthcare